Tyrer-Cuzick and NCCN: Quick Crash Course for Breast Centers in 2024
How NCCN Guidelines and the Tyrer-Cuzick Lifetime Model differ and why programs are missing patients.
How NCCN Guidelines and the Tyrer-Cuzick Lifetime Model differ and why programs are missing patients.
Our latest offerings underscore our commitment to the genetics community, high-risk program outcomes, and continued innovation in precision...
Breast center providers including mammography techs, nurses, and clinicians, as well as the patients they serve deserve a tool that helps them follow...
In a recent webinar hosted by the Association of Cancer Executives, CancerIQ’s Senior Vice President of Commercial Strategy, John Hansel, discussed...
Genomics has an established benefit in precision cancer care for patients and providers alike – but its positive financial impact on your health...
At the 10th Annual Clinical Cancer Genetics & Genomics Conference Haibo Lu and Matt Valin presented the challenges of high-risk cancer program design.
Health systems with top-tier high-risk breast program increase early detection, prevent costly late-stage cancer care, and improve survival rates.
President’s Cancer Panel: 5 takeaways on breast cancer screening, genetic testing access, and widening adoption of new technology.
Patient-centric best practices for operating genetics and high-risk cancer programs in the age of COVID-19.
Best Practices from CancerIQ partners engaging patients in virtual genetics and high-risk programs amidst a pandemic.